Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 15, 2021updated 06 Dec 2021 8:07am

Mesa Labs agrees to acquire Agena Bioscience for $300m

On closing the deal, Agena CEO Peter Dansky will head Mesa’s new Clinical Genomics Division.

Mesa Laboratories has signed a definitive agreement to acquire Agena Bioscience for a total of $300m in cash, subject to standard purchase price adjustments.

A US-based molecular diagnostics tools company, Agena creates, manufactures and distributes sensitive, cost-effective, high-throughput genetic analysis solutions for clinical labs and development partners across the globe.

The company’s MassArray system is an established platform that merges mass spectroscopy and multiplex polymerase chain reaction (PCR), to offer sensitivity, cost-effectiveness, fast turnaround time, ease of use and flexibility.

Mesa anticipates Agena to generate between $63m and $67m in revenue, plus an additional $3m to $5m in Covid-19 testing revenue, within one year of acquisition.

In the following years, Mesa expects continued organic revenue growth in high single digits, with gross profit margins around $60m, even if Covid-linked revenues reduce.

On concluding the acquisition, Agena CEO Peter Dansky will lead the new Clinical Genomics Division of Mesa.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Dansky said: “We are proud of our track record in bringing the power of genomics to the clinical setting in hereditary diseases, pharmacogenomics, oncology, infectious disease and sample integrity testing.

“We built our company based on a strong team-oriented values system, and we see a great fit with the Mesa culture.”

Jefferies served as the exclusive financial advisor, while DLA Piper (US) was the legal advisor to Agena.

Davis Graham & Stubbs was Mesa’s legal advisor.

Mesa plans to fund the all-cash deal through a combination of cash on hand and proceeds from its credit facility.

Subject to necessary conditions and regulatory approvals, the acquisition is anticipated to conclude in Mesa’s third fiscal quarter, ending 31 December.

Mesa designs and manufactures quality control solutions for medical devices, as well as pharmaceutical and healthcare industries.

It operates through Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments and Continuous Monitoring divisions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU